Volasertib

Drug Overview

Volasertib (formerly known as BI 6727) is an investigational, highly potent, and selective small-molecule inhibitor of Polo-like kinase 1 (Plk1). It belongs to the dihydropteridinone class of compounds and is designed to disrupt the cell division process (mitosis) in cancer cells. Plk1 is an enzyme that acts as a master regulator of mitosis; by inhibiting it, volasertib induces mitotic arrest and subsequent programmed cell death (apoptosis).

In the clinical landscape of March 2026, volasertib remains an investigational agent. It has been primarily developed for the treatment of Acute Myeloid Leukemia (AML), particularly in older patients who are not candidates for intensive “7+3” induction chemotherapy. While it was granted Breakthrough Therapy Designation by the FDA in 2013 based on early promising results, its clinical path has been complex due to challenges in large-scale Phase 3 trials.

• Generic Name: Volasertib.
• Code Name: BI 6727.
• Drug Class: Polo-like Kinase (Plk) Inhibitor; Antineoplastic Agent.
• Mechanism: Inhibition of Plk1, leading to mitotic “catastrophe” and apoptosis.
• Route of Administration: Intravenous (IV) infusion.
• FDA Approval Status: Investigational. As of March 2026, volasertib is not FDA-approved. It continues to be studied in specialized clinical trials and through expanded access programs for specific patient populations.

What Is It and How Does It Work? (Mechanism of Action)

Volasertib is a “mitotic inhibitor” that targets a specific protein required for cells to divide successfully.

1. Inhibition of Polo-like Kinase 1 (Plk1)

Plk1 is essential for several stages of mitosis, including the formation of the mitotic spindle and the separation of chromosomes. Cancer cells often “overexpress” Plk1 to fuel their rapid, uncontrolled growth.

• ATP-Competitive Binding: Volasertib binds to the ATP-binding pocket of the Plk1 enzyme, preventing it from performing its regulatory duties.
• Spindle Disruption: Without functional Plk1, the cell cannot properly align its chromosomes.

2. Mitotic Arrest and Apoptosis

When a cell is treated with volasertib, it enters a state called “polo-arrest.”

• Monastral Spindles: Instead of a normal two-sided spindle, the cell forms a “monastral” (one-sided) spindle that cannot pull chromosomes apart.
• Programmed Cell Death: The cell’s internal “checkpoints” recognize that division has failed, triggering apoptosis (cell suicide). This process is often called “mitotic catastrophe.”

FDA Approved Clinical Indications

There are currently no FDA-approved indications for volasertib.

Clinical research through 2026 has primarily focused on:

• Newly Diagnosed Acute Myeloid Leukemia (AML): Specifically in patients aged 65 or older who are unfit for intensive induction chemotherapy.
• Relapsed or Refractory AML: Evaluated as a single agent or in combination with other low-intensity therapies.
• Myelodysplastic Syndromes (MDS): Investigated for high-risk MDS patients who have failed prior hypomethylating agents (like azacitidine).
• Solid Tumors: Early-phase trials have explored its use in advanced solid tumors, although hematologic malignancies remain the primary focus.

Dosage and Administration Protocols

As an investigational drug, volasertib dosing is strictly controlled within clinical trials (such as the POLO-AML-1 and POLO-AML-2 trials).

Clinical Efficacy and Research Results

The clinical journey of volasertib has been a “rollercoaster” of results updated through 2025–2026:

• Phase 2 Success: A randomized Phase 2 trial showed that adding volasertib to LDAC significantly increased the complete remission (CR) rate and extended overall survival compared to LDAC alone.
• Phase 3 Challenges: The larger POLO-AML-2 Phase 3 trial did not meet its primary endpoint of significantly improving overall survival in the total study population, largely due to a higher rate of fatal infections in the volasertib arm.
• Ongoing Interest: Despite Phase 3 hurdles, researchers in 2026 are looking at biomarkers (such as Plk1 expression levels or specific genetic mutations) to identify a “responder” group of patients who may still benefit from the drug.

Safety Profile and Side Effects

The primary toxicity of volasertib is related to its effect on rapidly dividing cells, which includes healthy bone marrow and mucosal tissues.

Common Side Effects (>25%):

• Myelosuppression: A severe drop in white blood cells (Neutropenia), red blood cells (Anemia), and platelets (Thrombocytopenia). This is the dose-limiting toxicity.
• Gastrointestinal: Nausea, vomiting, and diarrhea.
• Mucositis: Painful inflammation and sores in the mouth and digestive tract.

Serious Risks:

• Febrile Neutropenia: Fever associated with very low white blood cell counts, which can lead to life-threatening sepsis.
• Infections: Pneumonia and fungal infections are significant risks due to prolonged suppressed immunity.
• Bleeding: Severe bleeding episodes due to low platelet counts.

Research Areas

In the fields of Stem Cell and Regenerative Medicine, volasertib is used to study “Mitotic Checkpoint Control.” Researchers are investigating how volasertib affects the Leukemic Stem Cell (LSC) niche. Unlike mature leukemia cells, LSCs are often dormant; scientists are exploring if volasertib can be combined with “priming” agents to force LSCs into the cell cycle where they become vulnerable to Plk1 inhibition. In 2026, there is also research into using volasertib to improve the “purity” of stem cell populations in the lab by selectively eliminating rapidly dividing contaminating cells.

Patient Management and Practical Recommendations

Pre-treatment Requirements:

• Bone Marrow Biopsy: Required to confirm the diagnosis and monitor the response to treatment.
• Cardiac Screening: Baseline assessments are often recommended, as with most intensive IV therapies.

“Do’s and Don’ts” List:

• DO report any fever higher than 38°C (100.4°F) immediately, as this is a medical emergency for patients on volasertib.
• DO maintain strict oral hygiene with alcohol-free mouthwashes to help prevent or manage mucositis.
• DON’T take any live-virus vaccines while receiving volasertib, as your immune system will be significantly weakened.
• DON’T ignore signs of unusual bruising or small red spots on the skin (petechiae), which could indicate dangerously low platelet levels.

Legal Disclaimer

The information provided is for educational and informational purposes only and does not constitute medical advice. Volasertib (BI 6727) is an investigational agent and is not currently approved by the U.S. FDA. Access is limited exclusively to registered clinical trials or specific expanded access programs. Always consult with a qualified oncologist regarding your specific diagnosis and eligibility for research participation.